Makiko Seimiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Makiko Seimiya has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Ariane Leoni Moore
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
1 shared publication - Christian Beisel
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
1 shared publication - Joana Torres
Division of Gastroenterology, Hospital da Luz, Lisbon, Portugal
1 shared publication - Jorge V. Beira
Department of Biosystems Science and Engineering, ETH Zurich, Basel, Switzerland
1 shared publication - Niko Beerenwinkel
Department of Biosystems Science and Engineering, ETH Zürich
1 shared publication - Remo Monti
Affiliations Digital Health Machine Learning, Hasso Plattner Institute for Digital Engineering, Potsdam, Germany, Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin Institute for Medical Systems Biology, Berlin, Germany
1 shared publication
Latest Publications
- Open Access
- 21 March 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
A switch in transcription and cell fate governs the onset of an epigenetically-deregulated tumor in Drosophila
Tumor initiation is often linked to a loss of cellular identity. Transcriptional programs determining cellular identity are preserved by epigenetically-acting chromatin factors. Although such regulators are among the most frequently mutated genes in cancer, it is not well understood how an abnormal epigenetic condition contributes to tumor onset. In this work, we investigated the gene signature of tumors caused by disruption of the Drosophila epigenetic regulator, polyhomeotic (ph). In larval tissue ph mutant cells show a shift towards an embryonic-like signature. Using loss- and gain-of-function experiments we uncovered the embryonic transcription factor knirps (kni) as a new oncogene. The oncogenic potential of kni lies in its ability to activate JAK/STAT signaling and block differentiation. Conversely, tumor growth in ph mutant cells can be substantially reduced by overexpressing a differentiation factor. This demonstrates that epigenetically derailed tumor conditions can be reversed when targeting key players in the transcriptional network.
- 21 March 2018
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 7
Open AccessA switch in transcription and cell fate governs the onset of an epigenetically-deregulated tumor in Drosophila
Tumor initiation is often linked to a loss of cellular identity. Transcriptional programs determining cellular identity are preserved by epigenetically-acting chromatin factors. Although such regulators are among the most frequently mutated genes in cancer, it is not well understood how an abnormal epigenetic condition contributes to tumor onset. In this work, we investigated the gene signature of tumors caused by disruption of the Drosophila epigenetic regulator, polyhomeotic (ph). In larval tissue ph mutant cells show a shift towards an embryonic-like signature. Using loss- and gain-of-function experiments we uncovered the embryonic transcription factor knirps (kni) as a new oncogene. The oncogenic potential of kni lies in its ability to activate JAK/STAT signaling and block differentiation. Conversely, tumor growth in ph mutant cells can be substantially reduced by overexpressing a differentiation factor. This demonstrates that epigenetically derailed tumor conditions can be reversed when targeting key players in the transcriptional network.